Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with β-thalassemia
- PMID: 21497638
- DOI: 10.1016/j.vaccine.2011.03.080
Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with β-thalassemia
Abstract
Natural and vaccine-induced immunity to meningococcus C (MenC) was evaluated in asplenic adolescents and adults with β-thalassemia. At baseline 19.3% of patients and 22.8% age-matched controls had positive (>2 μg/ml) naturally acquired Men C- specific IgG antibodies; patients had a lower probability of having protective SBA compared to controls (OR=21, p=0.012). MenC conjugate vaccine (MCC) induced protective IgG concentrations in 63% of patients and 90.1% of controls. SBA increased significantly post vaccination and there were no differences between patients and controls; however patients had significantly lower IgG concentrations post vaccination compared to controls (4.52 vs 10.94 μg/ml, p<0.001, respectively). A second dose of MCC given to 11 patients who had received MCC in the past induced higher IgG compared to primary response (p=0.001). Naturally- and vaccine-induced immunity to MenC is impaired in asplenic β-thalassemics; a second dose of MCC improves vaccine immunogenicity and is essential for their optimal protection.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609. Pediatr Infect Dis J. 2009. PMID: 19325450 Clinical Trial.
-
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.Pediatr Infect Dis J. 2011 Nov;30(11):e203-8. doi: 10.1097/INF.0b013e318224fb14. Pediatr Infect Dis J. 2011. PMID: 21673612 Clinical Trial.
-
The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.Int J Infect Dis. 2008 May;12(3):278-88. doi: 10.1016/j.ijid.2007.08.007. Epub 2007 Nov 5. Int J Infect Dis. 2008. PMID: 17981067 Clinical Trial.
-
Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Pediatr Infect Dis J. 2009. PMID: 19325452 Review.
-
Effectiveness of meningococcal serogroup C vaccine programmes.Vaccine. 2013 Sep 23;31(41):4477-86. doi: 10.1016/j.vaccine.2013.07.083. Epub 2013 Aug 9. Vaccine. 2013. PMID: 23933336 Review.
Cited by
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
-
Recommended vaccinations for asplenic and hyposplenic adult patients.Hum Vaccin Immunother. 2017 Feb;13(2):359-368. doi: 10.1080/21645515.2017.1264797. Hum Vaccin Immunother. 2017. PMID: 27929751 Free PMC article.
-
Vaccine coverage for recommended vaccines among splenectomised patients in Apulia, South Italy: a retrospective cohort study.BMJ Open. 2023 Mar 29;13(3):e069316. doi: 10.1136/bmjopen-2022-069316. BMJ Open. 2023. PMID: 36990496 Free PMC article.
-
Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.Pediatr Infect Dis J. 2015 May;34(5):e113-8. doi: 10.1097/INF.0000000000000630. Pediatr Infect Dis J. 2015. PMID: 25876102 Free PMC article.
-
Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 May;63(5):588-644. doi: 10.1007/s00103-020-03123-w. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 32350583 Free PMC article. German. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous